Roivant Sciences
ROIV
313 hedge funds and large institutions have $5.63B invested in Roivant Sciences in 2025 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 92 increasing their positions, 107 reducing their positions, and 59 closing their positions.
242% more call options, than puts
Call options by funds: $38.5M | Put options by funds: $11.2M
6% more funds holding in top 10
Funds holding in top 10: 17 → 18 (+1)
0.87% more ownership
Funds ownership: 77.28% → 78.15% (+0.87%)
5% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 59
2% less funds holding
Funds holding: 319 → 313 (-6)
14% less repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 107
15% less capital invested
Capital invested by funds: $6.65B → $5.63B (-$1.03B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$26.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.6M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$16.3M |
| 4 |
Morgan Stanley
New York
|
+$14.2M |
| 5 |
CCM
Cutter Capital Management
New York
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$35.9M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$28.9M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$24.1M |
| 4 |
State Street
Boston,
Massachusetts
|
-$21M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$20.5M |
ROIV Hedge Fund Activity: Q1 2025 in Review
313 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q1 2025, worth a combined $5.63B — down 15% from $6.65B a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of ROIV and 56 opened new positions — a net loss of 3 holders — while 107 trimmed existing stakes and 92 added.
The largest buyer was Dimensional Fund Advisors, adding an estimated $26.6M. The largest seller was Vanguard Group, cutting an estimated $35.9M.
- 313 institutional investors held Roivant Sciences (ROIV) as of Q1 2025, down from 319 in Q4 2024.
- Funds reported $5.63B of Roivant Sciences stock for Q1 2025, down 15% quarter-over-quarter.
- 56 funds opened new Roivant Sciences positions in Q1 2025 and 59 closed out, a net change of -3 holders.
- The largest Roivant Sciences buyer in Q1 2025 was Dimensional Fund Advisors, an estimated $26.6M added.
- The largest Roivant Sciences seller in Q1 2025 was Vanguard Group, an estimated $35.9M sold.
Based on aggregated 13F filings for Q1 2025.